Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2022-N-0413]
 AGENCY: Food and Drug Administration, Health and Human Service (HHS).
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 14 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of May 25, 2022.
 FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, 
                        *Martha.Nguyen@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
                    ( print page 24321) Application No.
Drug
ApplicantANDA 075695
Butorphanol Tartrate Injection, 1 milligram (mg)/milliliter (mL), and 2 mg/mL
Baxter Healthcare Corporation, One Baxter Pkwy., Deerfield, IL 60015.ANDA 075697
Butorphanol Tartrate Injection, 2 mg/mL
Do.ANDA 077290
Oxycodone Hydrochloride (HCl) Tablets, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
Nesher Pharmaceuticals (USA) LLC, 13910 St. Charles Rock Rd., Bridgeton, MO 63044.ANDA 078564
Granisetron HCl Injection, Equivalent to (EQ) 1 mg base/mL (EQ 1 mg base/mL)
Morton Grove Pharmaceuticals Inc., 6451 Main St., Morton Grove, IL 60053.ANDA 078565
Granisetron HCl Injection, EQ 4 mg base/4 mL (EQ 1 mg base/mL)
Do.ANDA 078566
Granisetron HCl Injection, EQ 0.1 mg base/mL (EQ 0.1 mg base/mL)
Do.ANDA 088342
Fluoxymesterone Tablets, 10 mg
Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369.ANDA 202032
Lamivudine Tablets, 150 mg and 300 mg
Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Rd., East Windsor, NJ 08520.ANDA 205322
Efavirenz Tablets, 600 mg
Do.ANDA 205690
Choline C-11 Injection, 4-100 millicurie/mL
University of Texas MD Anderson Cancer Center, 1881 East Rd., Unit 1903, Houston, TX 77054.ANDA 207653
Rosuvastatin Calcium Tablets, EQ 5 mg base, EQ 10 mg base, EQ 20 mg base, EQ 40 mg base
SciRegs International, Inc., 6333 Summercrest Dr., Columbia, MD 21045.ANDA 208199
Azelastine HCl Metered Spray, 0.2055 mg/spray
Amneal Pharmaceuticals LLC, 50 Horseblock Rd., Brookhaven, NY 11719.ANDA 210032
Azelastine HCl Metered Spray, 0.2055 mg/spray
Akorn Operating Company LLC, 1925 West Field Ct., Suite 300, Lake Forest, IL 60045.ANDA 211461
Bosentan Tablets, 62.5 mg and 125 mg
Syneos Health Global Headquarters, 1030 Sync St., Third Floor, Morrisville, NC 27560.
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of May 25, 2022. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on May 25, 2022 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: April 19, 2022. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2022-08744 Filed 4-22-22; 8:45 am] BILLING CODE 4164-01-P